Titre :

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Auteur(s) :

Cabannes-Hamy, Aurelie [Auteur]
Peyrade, Frederic [Auteur]
Jardin, Fabrice [Auteur]
Emile, Jean-Francois [Auteur]
Delwail, Vincent [Auteur]
Mounier, Nicolas [Auteur]
Haioun, Corinne [Auteur]
Perrot, Aurore [Auteur]
Fitoussi, Olivier [Auteur]
Lara, Diane [Auteur]
Delarue, Richard [Auteur]
Andre, Marc [Auteur]
Offner, Fritz [Auteur]
Ghesquieres, Herve [Auteur]
Pascal, Laurent [Auteur]
Soussain, Carole [Auteur]
Lazarovici, Julien [Auteur]
Schiano, Jean-Marc [Auteur]
Gaulard, Philippe [Auteur]
Tilly, Herve [Auteur]
Thieblemont, Catherine [Auteur]

Titre de la revue :

Cancer medicine

Nom court de la revue :

Cancer Med

Numéro :

7

Pagination :

539-548

Date de publication :

2018

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

CNS relapse is reported in 2-5% of diffuse large B-cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk factors of CNS relapse in very elderly patients, ...
Lire la suite >CNS relapse is reported in 2-5% of diffuse large B-cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk factors of CNS relapse in very elderly patients, a challenging population to treat given their commonly associated comorbidities. A retrospective analysis was performed of 270 DLBCL patients >80 years treated between 2004 and 2013 in two multicentre phase II LYSA trials (LNH03-7B, LNH09-7B) evaluating the addition of rituximab or ofatumumab to mini-CHOP as front-line therapy. No patients received CNS prophylaxis. CNS relapse was evaluated according to cumulative incidence, patient characteristics, risk factors, and survival. Median age was 83 years (range: 79-95). After a median follow-up of 28.7 months, eight patients had CNS relapse (3.0%). Median time between inclusion and CNS relapse was 19.2 months (range: 3.2-32.6). Patients survived a median of 1.5 months after CNS relapse (range: 0.4-4.1). Median OS from relapse was significantly lower in CNS relapse patients (1.5 months, 95% CI: 0.4-3.5) compared to patients with non-CNS relapse (6.6 months; 95% CI: 4.6-11.9). No baseline characteristics were associated with CNS relapse. The proportion of patients with CNS disease did not differ significantly between patients with low-intermediate risk according to CNS-IPI and patients with high risk (3% vs. 2.8%, P = 1.00). CNS relapse cumulative incidence in very elderly treatment-naive patients is 1.8% at 2 years and is associated with poor survival. This population had a long median time to CNS relapse. Absence of prophylaxis did not strongly impact CNS relapse incidence.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Équipe(s) de recherche :

Innovation/évaluation des médicaments injectables

Date de dépôt :

2019-02-26T17:06:58Z